Which COVID-19 vaccine (including brand and generic name) is most efficacious for adults aged ≥65 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

COVID-19 Vaccine Efficacy for Adults Over 65 Years

For patients over 65 years old, all three FDA-approved 2024-2025 COVID-19 vaccines (Moderna mRNA-1273, Pfizer-BioNTech BNT162b2, and Novavax) are recommended, with emerging evidence suggesting Moderna may provide marginally superior protection against infection and hospitalization in this age group.

Current ACIP Guideline Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged ≥65 years receive one dose of any 2024-2025 COVID-19 vaccine (Moderna, Pfizer-BioNTech, or Novavax) to remain up to date 1. This recommendation applies to:

  • Moderna mRNA-1273 (KP.2 strain-adapted)
  • Pfizer-BioNTech BNT162b2 (KP.2 strain-adapted)
  • Novavax (JN.1 strain-adapted, protein subunit vaccine)

All three vaccines target currently circulating Omicron variants and are FDA-approved or authorized for use in this population 1.

Why Vaccination Matters Most in This Age Group

Adults aged ≥65 years experience the highest rates of severe COVID-19, hospitalization, and death 1. Economic modeling demonstrates COVID-19 vaccines are most cost-effective in this population, with an incremental cost-effectiveness ratio of $23,308 per quality-adjusted life year—far more favorable than any other age group 1.

During 2023-2024, adults aged ≥75 years had the highest COVID-19 hospitalization rates, followed by those aged 65-74 years. In 2023 alone, 44,059 COVID-19-associated deaths occurred in persons aged ≥65 years 1.

Comparative Vaccine Effectiveness: The Evidence

Moderna vs. Pfizer-BioNTech

A 2024 meta-analysis of 24 real-world studies found Moderna (mRNA-1273) provided superior protection compared to Pfizer-BioNTech (BNT162b2) in adults aged ≥50 years 2:

  • SARS-CoV-2 infection: 28% lower risk (RR 0.72,95% CI 0.64-0.80)
  • Symptomatic infection: 28% lower risk (RR 0.72,95% CI 0.62-0.83)
  • Severe infection: 33% lower risk (RR 0.67,95% CI 0.57-0.78)
  • COVID-19 hospitalization: 35% lower risk (RR 0.65,95% CI 0.53-0.79)
  • COVID-19 death: No significant difference (RR 0.80,95% CI 0.64-1.00)

A 2025 indirect treatment comparison specifically in adults ≥65 years found Moderna's next-generation mRNA-1283 vaccine was 22.8% more effective than Pfizer-BioNTech against symptomatic COVID-19 (95% CI 3.7-38.1%, p=0.022) 3.

However, a 2026 UK study found similar outcomes between the two mRNA vaccines for COVID-19 hospitalization and death over 350 days of follow-up 4, suggesting real-world differences may be modest.

mRNA vs. Novavax

Direct comparative effectiveness data between mRNA vaccines and Novavax in older adults is limited. A 2022 meta-analysis found mRNA vaccines showed the best overall efficacy (90.72%) with the highest seroconversion rates (98.52%) and neutralizing antibody titers in older adults 5.

Emerging Self-Amplifying mRNA Technology

A 2026 Japanese study in adults ≥60 years found the JN.1-adapted self-amplifying mRNA (sa-mRNA) vaccine demonstrated 74.5% effectiveness (95% CI 31.3-90.6) at ≥7 days post-vaccination 6, though this technology is not yet available in the United States.

Practical Clinical Algorithm

For immunocompetent adults ≥65 years:

  1. Offer any 2024-2025 COVID-19 vaccine (Moderna, Pfizer-BioNTech, or Novavax)
  2. If choosing between mRNA vaccines and patient has no contraindications, Moderna may provide marginally better protection based on meta-analytic evidence
  3. Administer ≥8 weeks after last COVID-19 vaccine dose 1
  4. Single dose is sufficient for those previously vaccinated

For moderately/severely immunocompromised adults ≥65 years:

  1. Recommend mRNA vaccines (Moderna or Pfizer-BioNTech) over Novavax
  2. Administer 3-dose initial series if unvaccinated (all same manufacturer) 1
  3. Additional doses may be needed based on vaccination history

Important Safety Considerations

Statistical Signals in Older Adults

The Vaccine Safety Datalink identified two statistical signals for mRNA vaccines in the 2023-2024 season 1:

  • Guillain-Barré syndrome in persons aged ≥65 years (new signal, evidence inconclusive)
  • Ischemic stroke in adults aged ≥50 years (previously observed, cumulative data remain inconclusive)

Critical context: These signals have not been confirmed as actual risks, and any theoretical risk must be weighed against the substantial benefits of preventing COVID-19 and its complications—including stroke itself 1.

Adverse Events Profile

mRNA vaccines (particularly Moderna) cause higher rates of local and systemic adverse events (pain, fever, chills) compared to inactivated or protein-based vaccines 5. However, these are generally mild and self-limited.

Duration of Protection

Vaccine effectiveness wanes over time 4:

  • Greatest protection occurs in the first 70 days post-vaccination
  • Effectiveness against hospitalization: 69% at 7-59 days, declining to 32% at 120-179 days
  • This supports the rationale for annual updated vaccination

Common Pitfalls to Avoid

  1. Don't delay vaccination waiting for "the perfect vaccine"—all three options provide substantial protection, and timing matters given waning immunity
  2. Don't skip vaccination due to theoretical safety signals—the proven mortality benefit far outweighs unconfirmed risks
  3. Don't assume prior infection provides adequate protection—vaccination still recommended regardless of infection history
  4. Don't forget the 8-week interval if patient recently received a COVID-19 vaccine dose

Bottom Line for Clinical Practice

All three 2024-2025 COVID-19 vaccines are effective and recommended for adults ≥65 years, with Moderna showing modest superiority in meta-analyses but all three providing substantial protection against severe disease, hospitalization, and death. The most important decision is ensuring vaccination occurs, not which specific product is chosen. Given the highest disease burden and best cost-effectiveness in this age group, vaccination should be strongly encouraged for all eligible patients over 65.

References

Related Questions

For patients aged 65 and older, which mRNA COVID-19 vaccine—Spikevax (mRNA‑1273) or Comirnaty (BNT162b2)—offers superior efficacy?
Should a 67-year-old healthy female who received a COVID-19 (Coronavirus Disease 2019) vaccination in May of this year get a booster dose now?
Which COVID-19 vaccine product provides superior efficacy for patients aged 65 years and older—Moderna Spikevax (mRNA‑1273) or the next‑generation mNEXSPIKE?
How should cellulitis of the lower limb be managed in a patient with a total leukocyte count of 1400 cells/µL and neutrophils 74%?
For patients aged 65 and older, which mRNA COVID-19 vaccine—Spikevax (mRNA‑1273) or Comirnaty (BNT162b2)—offers superior efficacy?
Can a 39-year-old woman with a contrast media allergy use Vaseline (petroleum jelly) as a vaginal lubricant?
In a patient with a non‑acute aortic aneurysm who presented with symptoms two days ago and is already on aspirin and therapeutic enoxaparin, is it appropriate to add clopidogrel (Plavix)?
Which COVID-19 vaccine product provides superior efficacy for patients aged 65 years and older—Moderna Spikevax (mRNA‑1273) or the next‑generation mNEXSPIKE?
Is boric acid an effective treatment for vaginal candidiasis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.